These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 16886957

  • 1. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, Ranke MB, Price DA, KIGS International Board.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [Abstract] [Full Text] [Related]

  • 2. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
    Fillion M, Deal C, Van Vliet G.
    J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
    Lindgren AC, Lindberg A.
    Horm Res; 2008 Feb; 70(3):182-7. PubMed ID: 18663319
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [Abstract] [Full Text] [Related]

  • 5. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hübner C, Hokken-Koelega AC, KIGS Steering Committee.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1702-1711. PubMed ID: 28323917
    [Abstract] [Full Text] [Related]

  • 6. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E, Hughes I, Harris M, Ambler G, Crock P, Verge CF, Craig ME, Bergman P, Werther G, van Driel M, Davies PS, Choong CS.
    J Paediatr Child Health; 2013 Dec 01; 49(12):1045-51. PubMed ID: 23781979
    [Abstract] [Full Text] [Related]

  • 7. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
    Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO, KIGS International Board.
    Horm Res; 2007 Dec 01; 68(2):53-62. PubMed ID: 17228181
    [Abstract] [Full Text] [Related]

  • 8. Growth in pre-pubertal children with myelomeningocele (MMC) on growth hormone (GH): the KIGS experience.
    Trollmann R, Bakker B, Lundberg M, Doerr HG.
    Pediatr Rehabil; 2006 Dec 01; 9(2):144-8. PubMed ID: 16449073
    [Abstract] [Full Text] [Related]

  • 9. Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency.
    Schmidt H, Bechtold S, Schwarz HP.
    Eur J Med Res; 2000 Jul 19; 5(7):307-10. PubMed ID: 10903191
    [Abstract] [Full Text] [Related]

  • 10. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D, Garel C, Limoni C, Czernichow P, Léger J.
    Clin Endocrinol (Oxf); 2003 May 19; 58(5):647-52. PubMed ID: 12699449
    [Abstract] [Full Text] [Related]

  • 11. Growth response in prepubertal children with idiopathic growth hormone deficiency during the first two years of treatment with human growth hormone. Analysis of the Kabi Pharmacia International Growth Study.
    Ranke MB, Guilbaud O.
    Acta Paediatr Scand Suppl; 1991 May 19; 379():109-15; discussion 116. PubMed ID: 1815451
    [Abstract] [Full Text] [Related]

  • 12. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F, Ranke MB, Bakker B, Lindberg A, Cowell CT, Albertsson-Wikland K, Reiter EO, Price DA.
    Horm Res; 2005 May 19; 63(1):40-7. PubMed ID: 15627781
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal evaluation of sleep-disordered breathing in children with Prader-Willi Syndrome during 2 years of growth hormone therapy.
    Al-Saleh S, Al-Naimi A, Hamilton J, Zweerink A, Iaboni A, Narang I.
    J Pediatr; 2013 Feb 19; 162(2):263-8.e1. PubMed ID: 22947651
    [Abstract] [Full Text] [Related]

  • 14. Prader-Willi syndrome: who can have growth hormone?
    Stafler P, Wallis C.
    Arch Dis Child; 2008 Apr 19; 93(4):341-5. PubMed ID: 18089632
    [Abstract] [Full Text] [Related]

  • 15. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database.
    Darendeliler F, Karagiannis G, Wilton P.
    Horm Res; 2007 Apr 19; 68 Suppl 5():41-7. PubMed ID: 18174706
    [Abstract] [Full Text] [Related]

  • 16. Is growth hormone treatment in children associated with weight gain?--longitudinal analysis of KIGS data.
    Reinehr T, Lindberg A, Koltowska-Häggström M, Ranke M.
    Clin Endocrinol (Oxf); 2014 Nov 19; 81(5):721-6. PubMed ID: 24750131
    [Abstract] [Full Text] [Related]

  • 17. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment.
    Festen DA, de Weerd AW, van den Bossche RA, Joosten K, Hoeve H, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2006 Dec 19; 91(12):4911-5. PubMed ID: 17003096
    [Abstract] [Full Text] [Related]

  • 18. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome.
    Crinò A, Di Giorgio G, Manco M, Grugni G, Maggioni A.
    Horm Res; 2007 Dec 19; 68(2):83-90. PubMed ID: 17337902
    [Abstract] [Full Text] [Related]

  • 19. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE, Carrel AL, Whitman BY, Allen DB.
    J Pediatr; 2000 Jul 19; 137(1):42-9. PubMed ID: 10891820
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB, Carrel AL.
    J Pediatr Endocrinol Metab; 2004 Sep 19; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.